English-arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

News

January 15, 2025

Additional data from Affibody’s HER2 radiopharmaceutical program presented at PepTalk

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

News

January 10, 2025

Affibody regains rights in selected Asian countries to izokibep

Stockholm, Sweden, January 10, 2025. Affibody today announced that the company has regained rights to izokibep in selected Asian countries. In 2020, Affibody and Inmagene Biopharmaceuticals entered into a...

News

January 7, 2025

Affibody’s Nomination Committee for the 2025 Annual General Meeting

Stockholm, Sweden, January 7, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2025 Annual General Meeting (AGM) to be held on May...

Regulatory

December 10, 2024

Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis

Stockholm, Sweden, December 10, 2024. Affibody’s licensee ACELYRIN, INC. today announced that the Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint. Izokibep...

News

October 20, 2024

Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

News

September 19, 2024

Positive Results from Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Presented at EADV 2024 in Late-Breaking Session

Stockholm, Sweden, September 19, 2024. Affibody today announced that the positive results from a Phase 3 trial of izokibep in hidradenitis suppurativa will be presented at the 2024 European...

Regulatory

August 13, 2024

Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep

• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoint of HiSCR75 at week 12, as well as the key secondary endpoints of HiSCR90 and...

News

June 5, 2024

Positive 16-week Data From Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis Presented at EULAR 2024 Late Breaking Session

Stockholm, Sweden, June 5, 2024. Affibody today announced that positive 16-week data from a global Phase 2b/3 trial of izokibep in psoriatic arthritis (PsA) will be presented at the...

Regulatory

May 16, 2024

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 16, 2024 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...